New pill replicates exercise and strengthens muscles
A drug that replicates the benefits of exercise on bone and muscle in mice has been identified by researchers at Tokyo Medical and Dental University (TMDU).
Maintaining a regular exercise schedule can help you look and feel great, but did you know that exercise also benefits bone and muscle health? and cause bone deterioration. Recently, Japanese researchers discovered a new drug that may help treat exercise weakness by producing effects comparable to exercise.
Lack of exercise can lead to muscle weakness (known as sarcopenia) and bone loss (known as osteoporosis). Exercise overcomes this vulnerability by increasing muscle strength and increasing bone formation while reducing bone resorption. However, exercise therapy cannot be used in all clinical situations. Drug therapy can be very helpful in treating sarcopenia and osteoporosis if the patient has dementia, cerebrovascular disease, or is already bedridden. However, no drug targets both tissues simultaneously.
Researchers at Tokyo Medical and Dental University (TMDU) used a new drug screening system in a recent study published in the journal. bone research Identify compounds that mimic exercise-induced muscle and bone changes. Using a screening system, researchers discovered the aminoindazole derivative locamidazole (LAMZ). LAMZ has the ability to stimulate the growth of bone-forming osteoblasts and muscle cells while inhibiting the formation of bone-destroying osteoclasts.
LAMZ was successfully delivered to the bloodstream of mice without apparent side effects when administered orally. Taketo Ono, lead author of the study, said, “We were pleased to find that mice treated with LAMZ had wider muscle fibers, higher maximal strength, higher rates of bone formation, and lower bone resorption activity.” I think,” he said.
The research team further addressed the mode of function of LAMZ and found that LAMZ mimics calcium and PGC-1α signaling pathways. These pathways are activated during exercise and stimulate the expression of downstream molecules involved in muscle and bone maintenance.
To investigate whether LAMZ can treat locomotor disorders, we administered LAMZ to animal models of sarcopenia and osteoporosis. “Both oral and subcutaneous administration of the drug improved muscle and bone in locomotor frail mice,” said lead author Tomoki Nakashima.
Taken together, the research team’s findings indicate that LAMZ represents a potential therapeutic for the treatment of locomotor weakness by mimicking movement.
Reference: “Simultaneous Strengthening of Muscle and Bone by Exercise Mimicry by Calcium-PGC-1α Signaling” Takehito Ono, Ryosuke Denda, Yuta Tsukahara, Takashi Nakamura, Kazuo Okamoto, Hiroshi Takayanagi, Tomoki Nakajima, August 3, 2022 , bone research.
This research was supported by Japan Science and Technology Agency, Japan Agency for Medical Research and Development, Japan’s Ministry of Education, Culture, Sports, Science and Technology, Daiichi Sankyo Life Science Foundation, Takeda Science Foundation, and Secom Science and Technology Foundation.